Oral androgen receptor agonist improves sarcopenia over 52 weeks in men with cirrhosis

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data.
“Sarcopenia is common in cirrhosis and impacts clinically meaningful outcomes,” Arun Sanyal, MD, professor and director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, said during a presentation at EASL Congress. “There are multiple mechanisms that contribute to

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data.
“Sarcopenia is common in cirrhosis and impacts clinically meaningful outcomes,” Arun Sanyal, MD, professor and director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, said during a presentation at EASL Congress. “There are multiple mechanisms that contribute to